Literature DB >> 26490847

Low to moderate quality evidence demonstrates the potential benefits and adverse events of cannabinoids for certain medical indications.

Kevin P Hill1, W Max Hurley-Welljams-Dorof2.   

Abstract

Keywords:  CLINICAL PHARMACOLOGY; INTERNAL MEDICINE; PRIMARY CARE

Mesh：

Substances：

Year:  2015        PMID： 26490847     DOI： 10.1136/ebmed-2015-110264

Source DB:  PubMed          Journal:  Evid Based Med        ISSN： 1356-5524


× No keyword cloud information.
  2 in total

Review 1.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

2.  Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies.

Authors:  Dena Zeraatkar; Matthew Adam Cooper; Arnav Agarwal; Robin W M Vernooij; Gareth Leung; Kevin Loniewski; Jared E Dookie; Muhammad Muneeb Ahmed; Brian Y Hong; Chris Hong; Patrick Hong; Rachel Couban; Thomas Agoritsas; Jason W Busse
Journal:  BMJ Open       Date:  2022-08-04       Impact factor: 3.006
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.